Most Read Articles
Rachel Soon, 3 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

16 Mar 2019
Sleep difficulties are exacerbated in long-term survivors of childhood cancers, which may lead to persistent emotional distress, a new study has found.
2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 5 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

First-in-class CDK 4/6 inhibitor improves overall survival in advanced breast cancer patients

Dr. Joseph Delano Fule Robles
22 Oct 2018
Prof Massimo Cristofanilli. Photo from ESMO 2018.

Final analysis of results from the PALOMA-3 study showed improvement in overall survival (OS) with addition of cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib to fulvestrant in hormone receptorpositive, HER2-negative advanced breast cancer that has relapsed or progressed on hormonal therapy.

The final analysis of the prospective, randomized, phase III PALOMA-3 trial in 521 hormone receptorpositive, HER2-negative advanced breast cancer patients (median follow up, 44.8 months) showed that the median OS improved by 6.9 months with palbociclib plus fulvestrant vs placebo plus fulvestrant (34.9 months [95 percent confidence interval (CI), 28.8 to 40] vs 28 months [95 percent CI, 23.6 to 34.6]; p=0.043). [Cristofanilli M, et al, ESMO 2018, abstract LBA2_PR]

“This is the first report demonstrating that the absolute gain in [overall] survival is similar to the absolute gain in progression-free survival [PFS] in the whole population. This is very important to patients in terms of improving the chance of a long-term life in spite of advanced disease,” reported investigator Professor Massimo Cristofanilli of the Northwestern University, Feinberg School of Medicine, Chicago, US, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.

“The study was unpowered for OS so the data should be cautiously interpreted. Although the results strongly suggest that the PFS benefit may translate into OS benefit, the other trials conducted with CDK4/6 inhibitors will contribute to confirm the estimate of the OS benefit observed in this study,” commented discussant Dr Carmen Criscitiello of the European Institute of Oncology, Milan, Italy.  

Findings from the PALOMA-3 trial reported 2 years ago demonstrated that fulvestrant plus palbociclib was associated with significant and consistent improvement in PFS compared with fulvestrant plus placebo irrespective of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. [Lancet Oncol 2016;17:425-439]


Stay tuned for our full ESMO 2018 conference coverage

Read more:https://www.esmo.org/Press-Office/Press-Releases/PALOMA3-breast-cancer-palbociclib-fulvestrant-Cristofanilli

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 3 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

16 Mar 2019
Sleep difficulties are exacerbated in long-term survivors of childhood cancers, which may lead to persistent emotional distress, a new study has found.
2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 5 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.